Peroxisome proliferator-activated receptor γ (PPARγ), a target of thiazolidinediones used to treat patients with type 2 diabetes mellitus (T2DM), plays a crucial role in enhancing insulin sensitivity, promoting adipogenesis and exerting anti-inflammatory effects (Sauer, 2015; Stechschulte et al., 2016; Rao et al., 2015). Here, INS is linked to type 2 diabetes mellitus.